EVO 46135
Alternative Names: EVO-46135Latest Information Update: 28 Aug 2018
At a glance
- Originator Evec
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Metapneumovirus infections; Respiratory syncytial virus infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Metapneumovirus-infections in Japan (Parenteral)
- 28 Aug 2018 No recent reports of development identified for research development in Respiratory-syncytial-virus-infections in Japan (Parenteral)
- 06 Jul 2016 EVO 46135 is available for licensing as of 06 Jul 2016. http://www.evec.jp/